网站地图 联系我们 │ │ │ |
所况简介 机构设置 科研队伍 院地合作 党群园地 国际交流 博士后 研究生教育 信息公开
科研进展
成果报道
最新重要论文(影响因子PNAS及以上)
发表论文数据库
所级学术报告
科学成果
专题
所史丛书
所庆专辑
建所50周年画册
现在位置:  > 科研进展 > 最新重要论文(影响因子PNAS及以上)
CD146-HIF-1α hypoxic reprogramming drives vascular remodeling and pulmonary arterial hypertension,Nature Comm, 05 Sep 2019
2019-09-05 | 【     】【打印】【关闭

Nature Communications05 September, 2019,DOI:

CD146-HIF-1α hypoxic reprogramming drives vascular remodeling and pulmonary arterial hypertension

Yongting Luo, Xiao Teng, Lingling Zhang, Jianan Chen, Zheng Liu, Xuehui Chen, Shuai Zhao, Sai Yang, Jing Feng & Xiyun Yan

Abstract

Pulmonary arterial hypertension (PAH) is a vascular remodeling disease of cardiopulmonary units. No cure is currently available due to an incomplete understanding of vascular remodeling. Here we identify CD146-hypoxia-inducible transcription factor 1 alpha (HIF-1α) cross-regulation as a key determinant in vascular remodeling and PAH pathogenesis. CD146 is markedly upregulated in pulmonary artery smooth muscle cells (PASMCs/SMCs) and in proportion to disease severity. CD146 expression and HIF-1α transcriptional program reinforce each other to physiologically enable PASMCs to adopt a more synthetic phenotype. Disruption of CD146-HIF-1α cross-talk by genetic ablation of Cd146 in SMCs mitigates pulmonary vascular remodeling in chronic hypoxic mice. Strikingly, targeting of this axis with anti-CD146 antibodies alleviates established pulmonary hypertension (PH) and enhances cardiac function in two rodent models. This study provides mechanistic insights into hypoxic reprogramming that permits vascular remodeling, and thus provides proof of concept for anti-remodeling therapy for PAH through direct modulation of CD146-HIF-1α cross-regulation.

文章链接:

 

 

          
版权所有:韩国三级片     
地址:北京市朝阳区大屯路15号(100101) 电话:010-64889872
意见反馈联系人:侯文茹 电子邮件:houwenru@ibp.ac.cn